Latest & greatest articles for allopurinol

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on allopurinol or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on allopurinol and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for allopurinol

21. Meta-analysis of prophylactic allopurinol use in post-endoscopic retrograde cholangiopancreatography pancreatitis

Meta-analysis of prophylactic allopurinol use in post-endoscopic retrograde cholangiopancreatography pancreatitis Meta-analysis of prophylactic allopurinol use in post-endoscopic retrograde cholangiopancreatography pancreatitis Meta-analysis of prophylactic allopurinol use in post-endoscopic retrograde cholangiopancreatography pancreatitis Zheng M, Chen Y, Bai J, Xin Y, Pan X, Zhao L CRD summary This review reported that allopurinol treatment showed no significant benefit for the prevention (...) of post-endoscopic retrograde cholangiopancreatography pancreatitis. This review was generally well-conducted and the authors' conclusion is likely to be reliable. Authors' objectives To assess the efficacy and safety of allopurinol in the prevention of post-endoscopic retrograde cholangiopancreatography pancreatitis. Searching The following databases were searched from inception to July 2007: MEDLINE, EMBASE, and the Cochrane Central Register of Controlled Trials. Search terms were reported

DARE.2008

22. Meta-analysis: allopurinol in the prevention of postendoscopic retrograde cholangiopancreatography pancreatitis

Meta-analysis: allopurinol in the prevention of postendoscopic retrograde cholangiopancreatography pancreatitis Meta-analysis: allopurinol in the prevention of postendoscopic retrograde cholangiopancreatography pancreatitis Meta-analysis: allopurinol in the prevention of postendoscopic retrograde cholangiopancreatography pancreatitis Bai Y, Gao J, Zhang W, Zou D, Li Z CRD summary The review concluded that prophylactic allopurinol may not be useful for postendoscopic retrograde (...) cholangiopancreatography pancreatitis. This was a reasonably well conducted review. The authors' conclusions reflected the results of the review and appear likely to be reliable, but the lack of study details and statistical heterogeneity should be borne in mind. Authors' objectives To assess the effect of prophylactic allopurinol compared with placebo on pancreatitis following endoscopic retrograde cholangiopancreatography (ERCP). Searching MEDLINE, EMBASE, The Cochrane Library and Science Citation Index were

DARE.2008

23. Effect of allopurinol on blood pressure of adolescents with newly diagnosed essential hypertension: a randomized trial.

Effect of allopurinol on blood pressure of adolescents with newly diagnosed essential hypertension: a randomized trial. 18728266 2008 08 27 2008 09 02 2017 02 20 1538-3598 300 8 2008 Aug 27 JAMA JAMA Effect of allopurinol on blood pressure of adolescents with newly diagnosed essential hypertension: a randomized trial. 924-32 10.1001/jama.300.8.924 Hyperuricemia is a predictor for the development of hypertension and is commonly present in new-onset essential hypertension. Experimentally (...) at the Pediatric Hypertension Clinic at Texas Children's Hospital in Houston. Patients were excluded if they had stage 2 hypertension or known renal, cardiovascular, gastrointestinal tract, hepatic, or endocrine disease. Allopurinol, 200 mg twice daily for 4 weeks, and placebo, twice daily for 4 weeks, with a 2-week washout period between treatments. The order of the treatments was randomized. Change in casual and ambulatory blood pressure. For casual BP, the mean change in systolic BP for allopurinol was -6.9

JAMA2008 Full Text: Link to full Text with Trip Pro

24. Febuxostat compared with allopurinol in patients with hyperuricemia and gout.

Febuxostat compared with allopurinol in patients with hyperuricemia and gout. 16339094 2005 12 12 2005 12 20 2015 11 19 1533-4406 353 23 2005 Dec 08 The New England journal of medicine N. Engl. J. Med. Febuxostat compared with allopurinol in patients with hyperuricemia and gout. 2450-61 Febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase, is a potential alternative to allopurinol for patients with hyperuricemia and gout. We randomly assigned 762 patients with gout (...) and with serum urate concentrations of at least 8.0 mg per deciliter (480 micromol per liter) to receive either febuxostat (80 mg or 120 mg) or allopurinol (300 mg) once daily for 52 weeks; 760 received the study drug. Prophylaxis against gout flares with naproxen or colchicine was provided during weeks 1 through 8. The primary end point was a serum urate concentration of less than 6.0 mg per deciliter (360 micromol per liter) at the last three monthly measurements. The secondary end points included

NEJM2005

25. Allopurinol for chronic prostatitis.

Allopurinol for chronic prostatitis. BACKGROUND: Chronic prostatitis is a condition that causes men substantial morbidity through the associated constellation of urinary symptoms, sexual dysfunction, and pelvic pain. The etiology of chronic prostatitis is unknown, and the many and varied treatments for chronic prostatitis reflect in part this knowledge gap. One novel etiologic theory is that the reflux of urine into prostatic ducts causes prostatic inflammation via high concentrations of purine (...) and pyrimidine base-containing metabolites in prostatic secretions. This theory has led to the use of allopurinol for treatment of chronic prostatitis in hopes of lowering prostatic levels of uric acid and improving symptoms. OBJECTIVES: To determine the effects of allopurinol in the treatment of chronic prostatitis SEARCH STRATEGY: Trials were searched in computerized general and specialized databases (MEDLINE, Cochrane Library, Cochrane Prostate Group database), bibliographies of obtained articles

Cochrane2002

26. Allopurinol Neurocardiac Protection Trial in Infants Undergoing Heart Surgery Using Deep Hypothermic Circulatory Arrest

Allopurinol Neurocardiac Protection Trial in Infants Undergoing Heart Surgery Using Deep Hypothermic Circulatory Arrest PEDSCCM.org Criteria abstracted from series in Review Posted: founded 1995 Questions or comments?

PedsCCM Evidence-Based Journal Club2001

27. Allopurinol for chronic prostatitis.

Allopurinol for chronic prostatitis. OBJECTIVES: To determine the effects of allopurinol in the treatment of chronic prostatitis SEARCH STRATEGY: Trials were searched in computerized general and specialized databases (MEDLINE, Cochrane Library, Cochrane Prostate Group database), bibliographies of obtained articles, and direct contact with authors. SELECTION CRITERIA: All randomized trials of allopurinol versus placebo used to treat patients with chronic prostatitis. Acute prostatitis, bacterial (...) favoring allopurinol in patient-reported discomfort between the study and control groups at follow-up. Between days 45-225, the mean score was -0.95 (s.d. 0.19) for the allopurinol group (7 men), compared with -0.47 (s.d. 0.21) for the placebo group (7 men). The weighted mean difference (WMD) was -0.48 (95%CI -0.690, -0.270). The mean score between days 45-135 was -1.08 (s.d. 1.29) for the 25 men in the allopurinol group, compared with -0.21 (sd 0.97) for the 14 men in the control group. The WMD

Cochrane2000

28. Allopurinol in the treatment of American cutaneous leishmaniasis.

Allopurinol in the treatment of American cutaneous leishmaniasis. 1738379 1992 03 19 1992 03 19 2013 11 21 0028-4793 326 11 1992 Mar 12 The New England journal of medicine N. Engl. J. Med. Allopurinol in the treatment of American cutaneous leishmaniasis. 741-4 Pentavalent antimony, the generally accepted treatment for leishmaniasis, is given parenterally, and it is expensive and not readily available in developing countries. An inexpensive, orally administered compound would be a substantial (...) advance in treatment. Previous studies in vitro have shown synergism between allopurinol and pentavalent antimony in tissue-culture systems. We designed this clinical study to determine whether synergism could be demonstrated in patients. We performed a randomized, controlled study of the efficacy of allopurinol plus meglumine antimoniate (Glucantime), as compared with meglumine antimoniate alone, in patients with cutaneous leishmaniasis, who were recruited from a village in southeastern Colombia

NEJM1992

29. Randomized trial of allopurinol in the prevention of calcium oxalate calculi.

Randomized trial of allopurinol in the prevention of calcium oxalate calculi. 3534570 1986 12 15 1986 12 15 2013 11 21 0028-4793 315 22 1986 Nov 27 The New England journal of medicine N. Engl. J. Med. Randomized trial of allopurinol in the prevention of calcium oxalate calculi. 1386-9 In a double-blind study, we examined the efficacy of allopurinol in the prevention of recurrent calcium oxalate calculi of the kidney. Sixty patients with hyperuricosuria and normocalciuria who had a history (...) of calculi were randomly assigned to receive either allopurinol (100 mg three times daily) or a placebo. After the study, the placebo group had 63.4 percent fewer calculi (P less than 0.001), whereas the allopurinol group had 81.2 percent fewer calculi (P less than 0.001). During the study period, the mean rate of calculous events was 0.26 per patient per year in the placebo group and 0.12 in the allopurinol group. When the treatment groups were compared by actuarial analysis, the allopurinol group

NEJM1986

30. The effect of dietary protein on the clearance of allopurinol and oxypurinol.

The effect of dietary protein on the clearance of allopurinol and oxypurinol. 4033706 1985 10 11 1985 10 11 2013 11 21 0028-4793 313 13 1985 Sep 26 The New England journal of medicine N. Engl. J. Med. The effect of dietary protein on the clearance of allopurinol and oxypurinol. 771-6 A decrease in dietary protein is known to depress renal plasma flow and creatinine clearance. Using a randomized crossover design, we investigated the pharmacokinetics of allopurinol and its principal metabolite (...) , oxypurinol, after oral administration of 600 mg of allopurinol in six normal subjects receiving a high-protein (268 g per day) or low-protein (19 g per day) diet. For allopurinol, the area under the curve of plasma concentration versus time increased by a factor of 1.45 (P less than 0.02), the renal clearance decreased by 28 per cent (P less than 0.02), and the ratio of the clearance of allopurinol to that of creatinine (fractional excretion) was unchanged between the low-protein and high-protein diets

NEJM1985